

**SupplementaryTable 1. Summary of the clinicopathological characteristics of the patients with lung adecarcinomas examined for *EZH2* and *miR-101* expressions (N=149)**

Variable	Category	Frequency Count	Percent of Total Frequency
Gender	Female	73	48.99
	Male	76	51.01
Smoking Status	Current	64	42.95
	Former	66	44.30
	Never	19	12.75
T Stage (IASLC)	T1	45	30.20
	T2	74	49.66
	T3	25	16.78
	T4	5	3.36
N Stage (IASLC)	N0	100	67.11
	N1	28	18.79
	N2	21	14.09
TNM Stage IASLC	I	81	54.36
	II	38	25.50
	III	30	20.13
Adjuvant Therapy	No	93	62.42
	Yes	56	37.58
Vital Status	Alive	88	59.06
	Dead	61	40.94
Recurrence	No	88	59.06
	Yes	61	40.94

IASLC; International Association for the Study of Lung Cancer

**Supplementary Table 2. Association between markers' expression and lung adenocarcinoma patient's clinical and pathological characteristics (N=149)**

<b>Marker</b>	<b>Features</b>	<b>Category</b>	<b>Cases N</b>	<b>Mean</b>	<b>Median</b>	<b>P Value</b>
<b><i>EZH2</i></b>	Adjuvant Therapy	No	93	2.1	1.4	0.905
		Yes	56	2.0	2.1	
	Gender	Female	73	2.3	2.7	0.534
		Male	76	1.8	1.4	
	Smoking status	Never	19	6.5	6.9	<b>0.001*</b>
Ever		130	1.4	1.1		
Tumor Size	Tumor Size<=3.5cm	84	3.1	3.4	<b>0.049*</b>	
	Tumor Size>3.5cm	65	0.7	0.7		
Age (Median)	Age<=65	74	1.6	1.2	0.246	
	Age>65	75	2.5	3.8		
<b><i>miR-101</i></b>	Adjuvant Therapy	No	93	7.8	8.0	0.624
		Yes	56	7.8	7.9	
	Gender	Female	73	8.0	8.2	<b>0.001*</b>
		Male	76	7.6	7.7	
	Smoking status	Never	19	8.2	8.2	<b>0.012*</b>
Ever		130	7.8	7.9		
Tumor Size	Tumor Size<=3.5cm	84	7.8	8.1	0.293	
	Tumor Size>3.5cm	65	7.8	7.8		
Age (Median)	Age<=65	74	7.9	8.0	0.284	
	Age>65	75	7.7	7.9		

**Supplementary Table 3. Summary of Multivariate Analysis of Outcome in Lung Adenocarcinoma Patients by Adjuvant Chemotherapy and *EZH2*, *miR-101* and Combination of *EZH2/miR-101* Expression**

<b>Recurrence-Free Survival</b>							
<b>Multivariate Analysis</b>		<b>Adjuvant Therapy</b>			<b>No Adjuvant Therapy</b>		
<b>Parameter</b>	<b>Categories</b>	<b>HR<sup>±</sup></b>	<b>95%CI†</b>	<b>P value</b>	<b>HR<sup>±</sup></b>	<b>95%CI†</b>	<b>P value</b>
<b><i>EZH2</i> Expression</b>	Median	1.559	0.684; 3.552	0.290	0.909	0.437	1.890
Age	1 Year Increase						
TNM Stage IASLC	III vs I	2.959	1.034; 8.466	0.043	7.518	2.887	19.577
	II vs I	3.122	0.985; 9.897	0.053	1.035	0.428	2.502
Tumor Size	Median (3.5 cm)						
<b><i>miR-101</i> Expression</b>	Median	2.400	0.992; 5.810	0.052	0.621	0.293; 1.314	0.212
Age	1 Year Increase						
TNM Stage IASLC	III vs I	2.390	0.823; 6.946	0.109	7.907	3.083; 20.277	<0.0001
	II vs I	3.270	1.031; 10.378	0.044	1.059	0.441; 2.541	0.898
Tumor Size	Median (3.5 cm)						
<b><i>EZH2</i><sup>High</sup>/<i>miR-101</i><sup>Low</sup></b>	<i>EZH2</i> <sup>High</sup> / <i>miR-101</i> <sup>Low</sup> vs Others	1.915	0.734; 4.993	0.184	0.470	0.197; 1.119	0.088
Age	Median						
TNM Stage IASLC	III vs I	2.371	0.773; 7.270	0.131	8.806	3.383; 22.920	<0.0001
	II vs I	2.779	0.855; 9.027	0.089	1.045	0.436; 2.504	0.921
Tumor Size	Median (3.5 cm)						
<b>Overall Survival</b>							
<b>Multivariate Analysis</b>		<b>Adjuvant Therapy</b>			<b>No Adjuvant Therapy</b>		
<b>Parameter</b>	<b>Categories</b>	<b>HR<sup>±</sup></b>	<b>95%CI†</b>	<b>P value</b>	<b>HR<sup>±</sup></b>	<b>95%CI†</b>	<b>P value</b>
<b><i>EZH2</i> Expression</b>	Median	2.330	0.956; 5.678	0.062	1.146	0.545; 2.407	0.719
Age	1 Year Increase	1.023	0.979; 1.070	0.307	1.045	1.003; 1.090	0.037
TNM Stage IASLC	III vs I	10.929	1.374; 86.967	0.023	4.423	1.472; 13.388	0.008
	II vs I	8.117	0.973; 67.734	0.053	0.940	0.379; 2.333	0.893
Tumor Size	Median (3.5 cm)	1.281	1.051; 1.562	0.014	1.172	0.995; 1.380	0.057
<b><i>miR-101</i> Expression</b>	Median	0.529	0.200; 1.397	0.198	0.984	0.466; 2.075	0.965
Age	1 Year Increase	1.022	0.978; 1.067	0.330	1.045	1.003; 1.090	0.036
TNM Stage IASLC	III vs I	11.248	1.427; 88.648	0.021	4.523	1.497; 13.663	0.007
	II vs I	8.822	1.055; 73.762	0.044	0.971	0.397; 2.373	0.947
Tumor Size	Median (3.5 cm)	1.337	1.104; 1.610	0.003	1.165	0.990; 1.371	0.066
<b><i>EZH2</i><sup>High</sup>/<i>miR-101</i><sup>Low</sup></b>	<i>EZH2</i> <sup>High</sup> / <i>miR-101</i> <sup>Low</sup> vs Others	2.087	0.814; 5.352	0.125	0.794	0.341; 1.851	0.593
Age	1 year increase	1.020	0.977; 1.065	0.363	1.045	1.003; 1.090	0.037
TNM Stage IASLC	III vs I	9.174	1.105; 76.148	0.040	4.849	1.572; 14.955	0.006
	II vs I	7.280	0.868; 61.046	0.067	1.013	0.415; 2.273	0.978
Tumor Size	Median (3.5 cm)	1.277	1.053; 1.548	0.013	1.150	0.975; 1.355	0.096

<sup>±</sup>HR= Hazard ratio; CI†: confidence interval